Amgen Q1 2026 slides: six growth drivers fuel 24% expansion By Investing.com

Amgen reported Q1 2026 revenue of $8.6 billion, up 6% year over year, and non-GAAP EPS of $5.15, both ahead of expectations, while raising full-year guidance for revenue to $37.1 billion-$38.5 billion and EPS to $21.70-$23.10. Key growth brands including Repatha (+34%), EVENITY (+27%), TEZSPIRE (+20%), and the rare disease and oncology portfolios supported 24% aggregate growth across six core franchises, even as the stock fell 2.43% after hours. The company also increased its dividend 6% to $2.52 per share and continued advancing MariTide and other late-stage pipeline programs.

Analysis

The key takeaway is not the quarter itself, but the mix shift: Amgen is proving it can replace legacy cash cows with a broader set of franchise contributors while keeping margins unusually high for a company still ramping R&D. That matters because the market typically over-penalizes biopharma names during patent cliffs; here, the diversification across cardiovascular, bone, inflammation, rare disease, and oncology reduces the probability of a single product failure becoming a multiple compression event.

The second-order winner is likely not just AMGN, but the ecosystem around higher-complexity specialty care: specialty pharmacy, infusion channels, diagnostics, and select biotech tools suppliers tied to trial intensity and biologics manufacturing should see more durable demand. The big competitive pressure is on GLP-1 leaders and anti-obesity peers: if MariTide’s Phase 3 package reads as differentiated on maintenance or tolerability, the market will start pricing a credible third lane in obesity, which could compress the assumed terminal share of incumbent franchises. The larger risk is that investors are discounting pipeline breadth but still demanding a near-term catalyst that validates one of the new growth engines at blockbuster scale.

The stock’s post-print weakness looks more like skepticism about durability than disbelief in the quarter. That creates a favorable setup for a staged re-rating if the company continues to convert pipeline progress into label expansions over the next 6-12 months; conversely, any setback in MariTide or slower-than-expected uptake in Repatha/TEZSPIRE would expose the valuation to derating because the market is currently paying for execution, not just current earnings. The hidden concern is that high R&D intensity is now necessary to sustain the growth narrative, so a miss in 2026 pipeline milestones would hit both the top line story and the margin premium simultaneously.

Key Decisions for Investors

• Buy AMGN on 1-3 month weakness, targeting a re-test of pre-print levels; risk/reward is attractive because the current pullback appears to price in pipeline skepticism more than earnings deterioration.
• Pair trade: long AMGN / short a basket of mature large-cap pharma with heavier patent-cliff exposure over 3-6 months; AMGN has more visible self-help and less binary erosion risk.
• For higher-conviction upside, initiate a bullish call spread in AMGN with 6-12 month tenor to capture MariTide and label-expansion optionality while limiting downside if obesity data disappoints.
• Stay cautious on obesity incumbents with crowded narratives; if MariTide advances cleanly, expect sentiment pressure on GLP-1-adjacent names over the next 2-4 quarters.
• Use any further post-earnings compression to add, but size down ahead of the next major Phase 3 readout window since the stock will likely trade on pipeline credibility rather than current earnings until then.